Home|Journals|Articles by Year|Audio Abstracts
 

Original Article



Potential cytotoxic effects of borax alone and in combination with irinotecan on YKG1 glioblastoma cell-line

Yasemin Yuksel, Sefa Celik, Esra Aslan, Murat Tosun, Mukremin Uysal, Mehmet Bilgehan Pektas.




Abstract

Glioblastoma Multiforme (GBM), which is a common and primary brain tumor in adults, is an important cause of death worldwide as an aggressive and treatment-resistant cancer tumor. In this cell culture study, the apoptotic and anti-proliferative effects of borax and irinotecan at different doses, alone or in combination, were investigated in the YKG1 cell line. Cytotoxic activities were analyzed by MTT method and TUNEL staining after 24th and 48th hours of incubation with borax administered at doses of 1mg and 3mg per ml; irinotecan 50mM and 100mM. Both irinotecan and borax have been shown to induce apoptosis when used alone, and thus cause anti-proliferation. It was determined that these effects were potentiated by the combined application of the agents. In addition, it was determined that this effect in combined applications was more pronounced after 48 hours and at higher doses. In light of the data obtained, the combination of irinotecan with borax to increase the cytotoxic effect of irinotecan, which is used in many different cancer types, can be tried in further prospective studies.

Key words: YKG1, irinotecan, borax, MTT, Tunel






Full-text options


Share this Article


Online Article Submission
• ejmanager.com




ejPort - eJManager.com
Refer & Earn
JournalList
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.